Regeneron Pharmaceuticals: Expansion of Dupixent to Additional Indications & Other Key Developments! 

Regeneron Pharmaceuticals reported a solid financial and operational performance for the third quarter of 2024, highlighting key successes but also facing certain market challenges. Total revenue for Q3 2024 saw an 11% increase year-over-year, amounting to $3.72 billion, primarily fueled by stronger Sanofi collaboration revenues and growth in key products like Dupixent and EYLEA HD. Dupixent sales continue to impress with a 24% increase in global revenues to $3.8 billion. This growth was supported by favorable market reception and regulatory approvals across several jurisdictions for new indications, including chronic obstructive pulmonary disease (COPD). EYLEA HD and EYLEA combined net product sales reached $1.54 billion, a 3% increase, with EYLEA HD contributing significantly since its launch.